| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442439 | European Journal of Cancer | 2015 | 8 Pages |
Abstract
This analysis demonstrates that the combination of dabrafenib and trametinib provides better preservation of HRQoL and pain improvements versus dabrafenib monotherapy while also delaying progression. (Clinicaltrials.gov registration number: NCT01584648).
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Dirk Schadendorf, Mayur M. Amonkar, Daniil Stroyakovskiy, Evgeny Levchenko, Helen Gogas, Filippo de Braud, Jean-Jacques Grob, Igor Bondarenko, Claus Garbe, Celeste Lebbe, James Larkin, Vanna Chiarion-Sileni, Michael Millward, Ana Arance, Mario Mandalà ,